Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 30;22(1):112.
doi: 10.1186/s12969-024-01046-3.

Approaches and outcomes of adalimumab discontinuation in patients with well-controlled inflammatory arthritis: a systematic search and review

Erin Balay-Dustrude #  1   2 , Jessica Fennell #  3 , Kevin Baszis  4 , Y Ingrid Goh  5   6 , Daniel B Horton  7   8   9 , Tzielan Lee  10 , Chloe Rotman  11 , Anna Sutton  12 , Marinka Twilt  13 , Olha Halyabar  14 ; CARRA JIA Inactive Disease Workgroup
Affiliations

Approaches and outcomes of adalimumab discontinuation in patients with well-controlled inflammatory arthritis: a systematic search and review

Erin Balay-Dustrude et al. Pediatr Rheumatol Online J. .

Abstract

Objective: This systematic search and review aimed to evaluate the available literature on discontinuation of adalimumab and other tumor necrosis factor inhibitors (TNFi) for patients with well-controlled chronic inflammatory arthritides.

Methods: We conducted a publication search on adalimumab discontinuation from 2000-2023 using PubMed, CINAHL, EMBASE, and Cochrane Library. Included studies evaluated adalimumab discontinuation approaches, tapering schemes, and outcomes including successful discontinuation and recapture after flare, in patients with well-controlled disease. Studies included evaluated rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenile idiopathic arthritis (JIA).

Results: Forty-nine studies were included. Studies evaluating adalimumab alone were limited, and many reported TNFi outcomes as a single entity. Studies on rheumatoid arthritis (RA) (32, 8 RCTs) reported flare rates from 33-87%. Flares with medication tapering were slightly lower than with abrupt stop, and successful recapture was generally high (80-100%). Studies on spondyloarthropathy (12, 4 RCTs), focused on tapering, noting lower flare rates in tapering rather than abruptly stopping, and high recapture rates (~ 90%). Studies on JIA (5) were observational and demonstrated modestly lower flare rates with tapering (17-63%) versus abrupt stopping (28-82%). There was notable variability in study design, follow-up duration, specificity for TNFi results, and controlled pediatric studies.

Conclusion: The literature evaluating adalimumab and other TNFi discontinuation, flare rates, and recapture success within the inflammatory arthritis population demonstrated less flare when medications were tapered, over abrupt stop in the RA, spondyloarthropathy, and JIA populations. When medications were restarted after flare, recapture of well-controlled disease was generally high in RA and spondyloarthropathy, and generally favorable in JIA.

Keywords: Adalimumab; Juvenile idiopathic arthritis; Medication discontinuation; Rheumatoid arthritis; Spondyloarthritis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This manuscript has been reviewed and approved by all contributing authors; all work is original. This work did not require IRB approval. Consent for publication: Not applicable. Competing interests: DBH received research funding and salary support from the Childhood Arthritis and Rheumatology Research Alliance. All remaining authors involved in this manuscript have no other conflicts of interest related to this work to disclose.

Figures

Fig. 1
Fig. 1
PRISMA diagram of manuscript selection. *Non-rheumatic disease defined as disease not primarily managed by a rheumatologist including GI conditions such as IBD and dermatologic conditions such as psoriasis
See this image and copyright information in PMC

References

    1. Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2009;11(1):1–11. - PMC - PubMed
    1. Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2006;20(5):849–63. - PMC - PubMed
    1. van Rossum MAJ, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJW, Franssen MJAM, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis. 2007;66(11):1518–24. - PMC - PubMed
    1. Lovell DJ, Johnson AL, Huang B, Gottlieb BS, Morris PW, Kimura Y, et al. Risk, timing, and predictors of disease flare after discontinuation of anti-tumor necrosis factor therapy in children with polyarticular forms of juvenile idiopathic arthritis with clinically inactive disease. Arthritis Rheumatol. 2018;70(9):1508–18. - PMC - PubMed
    1. Aga AB, Lie E, Uhlig T, Olsen IC, Wierød A, Kalstad S, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010. Ann Rheum Dis. 2015;74(2):381–8. - PubMed

Publication types

MeSH terms

LinkOut - more resources